Seawolf Therapeutics Secures $100 Million and $1.2 Billion Sanofi Pact for Redosable DNA Medicines
Trendline

Seawolf Therapeutics Secures $100 Million and $1.2 Billion Sanofi Pact for Redosable DNA Medicines

What's Happening? Seawolf Therapeutics, a San Diego-based biotech company, has emerged with $100 million in Series A funding and has simultaneously entered into an alliance with Sanofi worth up to $1.2 billion. This partnership aims to develop new redosable DNA medicines. The Series A funding round
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.